Authors
Latest:
Performance Metrics in OncologyIn 2011, the Medicare Electronic Health Record Incentive Program began paying physicians and hospitals for the measurement and reporting of performance metrics through the utilization of certified electronic medical record software.
Latest:
Metadata: An Orwellian Big Brother within Electronic Medical RecordsConsider this hypothetical situation: A patient with new onset of a major depression is evaluated by a physician who has found no evidence of suicidal ideation.
Latest:
Dr. Uldrick on Rituximab Plus Liposomal Doxorubicin in HIV-Infected Patients With KSHV-MCDThomas S. Uldrick, MD, staff clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research at the National Institutes of Health, discusses long-term data from a study examining rituximab plus liposomal doxorubicin in HIV-infected patients with Kaposi sarcoma (KS) herpes virus-associated multicentric Castleman disease.
Latest:
Thomas Dubensky on How ADU-S100 Activates STINGThomas W. Dubensky Jr, PhD, chief scientific officer, Aduro Biotech, discusses a study of ADU-S100 and how it activates the human STING receptor, which is found to have presence in multiple tumor types.
Latest:
Dr. Flaig on Immune Checkpoint Inhibitors in Advanced Bladder CancerThomas W. Flaig, MD, discusses the utility of immune checkpoint inhibitors in advanced bladder cancer.
Latest:
Dr. LeBlanc Discusses End-of-Life Care for Hematologic MalignanciesThomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.
Latest:
HPV Test With Genotyping Tops Cervical Cancer Screening StrategiesCervical cancer screening based on identification of human papillomavirus (HPV) strains outperformed primary liquid cytology for detection of high-grade cervical intraepithelial neoplasia (CIN), data from a large cohort study showed.
Latest:
Dr Zhang on Topics of Ongoing Debate Within Prostate CancerTian Zhang, MD, MHS, discusses areas of ongoing debate regarding prostate cancer management.
Latest:
Series Wrap-up: Novel Therapies for mRCCA panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.
Latest:
Dr. Li Reviews Afatinib Data From the LUX-Lung 3 TrialTianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.
Latest:
Targeted Therapies and Biomarkers for SCLC: What’s Next on the HorizonPanelists discuss how emerging targeted and biomarker-directed therapies are poised to transform the treatment landscape for both limited-stage and extensive-stage small cell lung cancer, highlighting the potential for improved patient outcomes through personalized approaches.
Latest:
Evolving Treatment Paradigm in HER+ Breast Cancer: Future DirectionsKey opinion leaders anticipate future developments in HER2-positive breast cancer, and on the potential for translating therapeutic advances from the metastatic landscape into early-stage disease management.
Latest:
Addressing Treatment Gaps in HER2+ MBCUnmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.
Latest:
Consequences of Chemotherapy-Induced NeutropeniaA panel of breast oncologists define chemotherapy-induced neutropenia in terms of how they assess risk and attempt to prevent treatment-related toxicities in patients with cancer.
Latest:
Dr. Greten on the Tumor Microbiome and Antitumor Immunity in Liver CancerTim F. Greten, MD, discusses the role of the gut microbiome in antitumor immunity in liver cancer.
Latest:
Dr. Larson on Ongoing Trials in Colorectal CancerTim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).
Latest:
The Era of Interrogating Single Cells in Cancer Biopsy Is NowEven in seemingly uniform cell populations within subcompartments, cell-cell heterogeneity is becoming more evident, far beyond what was previously expected.
Latest:
Dr. Iveson on the IDEA Collaboration in CRCTim Iveson, MD, FACP, discusses the International Duration Evaluation of Adjuvant Chemotherapy Collaboration, which examines the effects of adjuvant oxaliplatin-based therapy given for 3 months versus 6 months in patients with high-risk stage II colorectal cancer.
Latest:
Tim Turnham on the Melanoma Research FoundationDr. Tim Turnham the executive director of the melanoma research foundation Describes the organization
Latest:
Dr. Patel on Sequencing Therapy in Rectal CancerTimil Patel, MD, discusses an optimal sequencing strategy in rectal cancer.
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology CareUSPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.
Latest:
Dr. Burns on the Evolving Use of ADCs in HER2-mutant NSCLCTimothy Burns, MD, PhD, discusses the evolving use of antibody-drug conjugates in HER2-mutant non–small cell lung cancer.
Latest:
Dr. Fenske on the Utility of Next-Generation BTK Inhibitors in MCLTimothy Fenske, MD, MS, discusses the utility of next-generation BTK inhibitors in mantle cell lymphoma.
